OncRef

Clinical Trial: NCT04079712

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-09-22

Study Overview

Brief Summary

This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab and ipilimumab may shrink the cancer.

Official Title

A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

Conditions

Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm, Metastatic Small Cell Neuroendocrine Carcinoma

Intervention / Treatment

  • Drug: Cabozantinib S-malate
  • Biological: Ipilimumab
  • Biological: Nivolumab

Other Study ID Numbers

  • NCI-2019-05864
  • NCI-2019-05864
  • 10315
  • 10315
  • UM1CA186689
  • UM1CA186691

Start Date (Actual)

2020-08-06

Primary Completion Date (Actual)

2025-01-10

Study Completion Date (Estimated)

2027-09-02

Enrollment (Actual)

17

Study Type

Interventional

Phase

Phase 2